DiaMedica Therapeutics Inc DMAC

Healthcare Biotechnology

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

NDAQ:DMAC - Post by User

DiaMedica Therapeutics Inc

Bullboard Posts

Post by Winnipeg40on Sep 27, 2013 12:03am

217 Views

Post# 21771955

Interesting trading

Two possibilities. 1) Some people are nibbling with news close at hand on the trials or,2) things are a bit leaky and those in the know are trying to get some more shares without driving the price up too much. I am still puzzled about the block of shares at 1.40 but that might be the last of the Crocus Fund holdings
I am hoping and betting on leaky with GOOD NEWS

Bullboard Posts

The top TSX healthcare stocks under $1